Plabix 75mg Tablet

Acute coronary syndrome – Initiate clopidogrel tablets with a single 300 mg oral loading dose and then continue at 75 mg once daily. – Initiating clopidogrel tablets without a loading dose will delay establishment of an antiplatelet effect by several days. Recent MI, recent stroke, or established peripheral arterial disease: 75 mg once daily orally without a loading dose.

Directions from the U.S. FDA-approved label for Clopidogrel — your doctor or pharmacist may advise differently.

Active pathological bleeding, such as peptic ulcer or intracranial hemorrhage Hypersensitivity to clopidogrel or any component of the product 4.1 Active Bleeding Clopidogrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. 4.2 Hypersensitivity Clopidogrel tablets are contraindicated in patients with hypersensitivity (e.g., anaphylaxis) to clopidogrel or any component of the product.

Excerpt from the U.S. FDA-approved label for Clopidogrel. Talk to a pharmacist or doctor before use.

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. Bleeding: Clopidogrel increases risk of bleeding. Discontinuation: Premature discontinuation increases risk of cardiovascular events. Discontinue 5 days prior to elective surgery that has a major risk of bleeding. Thrombotic thrombocytopenic purpura (TTP) has been reported. Cross-reactivity among thienopyridines has been reported. 5.1 Diminished Antiplatelet Activity in Patients with Impaired CYP2C19 Function Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is achieved through an active metabolite.

Warnings and precautions excerpt from the U.S. FDA-approved label for Clopidogrel — not a complete list. Talk to a pharmacist or doctor before use.

The following serious adverse reactions are discussed below and elsewhere in the labeling: Bleeding Thrombotic thrombocytopenic purpura Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction. To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Excerpt from the U.S. FDA-approved label for Clopidogrel — not a complete list. Talk to a pharmacist or doctor about side effects.

20 brands · 17 makers in the NepalDoc catalog — see the full Clopidogrel guide →

Store at 20° to 25°C (68° to 77°F); Protect from moisture.

Storage information from the U.S. FDA-approved label for Clopidogrel.